RxDoctor Payments Data

Toussaint Smith, MD

Cardiovascular Disease · Sugar Land, TXNPI 1902843949

Payments from drug & device makers

$12,024in general payments, 2019–2025

Across 578 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Sanofi-aventis U.S. LLC$1K
  • Novartis$1K
  • Amgen$987
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$800
  • Merck$773
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$9007%
  • Food & beverage$11,07592%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,024 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$364,345
Medicare patients
2,307
Services billed
5,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban645$528,454
XareltoRivaroxaban195$201,226
EntrestoSacubitril/Valsartan179$150,336
Repatha SureclickEvolocumab89$72,862
BrilintaTicagrelor53$31,045
NexlizetBempedoic Acid/Ezetimibe29$24,312
FarxigaDapagliflozin Propanediol18$12,757
Prazosin Hcl309$11,189
Praluent PenAlirocumab20$9,993
Metoprolol Succinate573$9,277
Hydralazine Hcl861$8,970
EdarbyclorAzilsartan Med/Chlorthalidone19$7,432
Diltiazem 24hr Er (Cd)Diltiazem Hcl201$6,082
Rosuvastatin Calcium434$5,894
NorvascAmlodipine Besylate11$5,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$521$528,454645 claims
Johnson & JohnsonXarelto$1,153$201,226195 claims
NovartisEntresto$1,110$150,336179 claims
AstraZenecaBrilinta, Farxiga$684$43,80271 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$104$29,42541 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$57$7,43219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →